BioWorld

July 9, 2003

Killer Clots That Attack Heart, Brain Countered By Clot-Busting Drugs Linked To Red Blood Cells

XOMA Regains Full Rights To Neuprex As Baxter Pulls Out

AEterna To Raise C$35.6M Upon Entering Bought-Deal Agreement

Other News To Note

Amgen Files With FDA Seeking Approval Of Enbrel In Psoriasis

Amgen Inc.'s Enbrel could be the first TNF blocker to make it to market as a treatment for psoriasis, an inflammatory disease often mischaracterized as a disease of the skin. (BioWorld Today) Read More

Genentech's Avastin Rights Outside U.S. Go To Roche

Today's news in brief

BioWorld

BioWorld briefs for Feb. 3, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...

Illustration of brain with neuron receptor

5-HT2R allosteric ligands attenuate cocaine use and seeking behavior

BioWorld Science

Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...